OX-40 Receptor Emerging
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>OX</strong>-<strong>40</strong> <strong>Receptor</strong> <strong>Emerging</strong> as a Novel<br />
Target in Cancer Immunotherapy<br />
enquiry@psmarketresearch.com<br />
www.psmarketresearch.com
<strong>OX</strong>-<strong>40</strong> <strong>Receptor</strong> Agonist Therapeutics<br />
<strong>OX</strong>-<strong>40</strong> receptor agonist therapeutics pipeline in 2017<br />
The study analyzed that the <strong>OX</strong>-<strong>40</strong> receptor agonist therapeutics pipeline<br />
comprises approximately nine drug candidates in different stages of<br />
development. <strong>OX</strong>-<strong>40</strong> is a costimulatory receptor that binds to its only known<br />
ligand, <strong>OX</strong>-<strong>40</strong>L, initiating cellular signaling events required for full activation of T<br />
cells following their recognition of a foreign antigen. <strong>OX</strong>-<strong>40</strong> agonists mimic the<br />
effect of <strong>OX</strong>-<strong>40</strong>L, and boost the <strong>OX</strong>-<strong>40</strong> signaling, and thereby leads to the<br />
suppression of the anti-tumor immune response in cancer patients. <strong>OX</strong>-<strong>40</strong><br />
agonists in combination with checkpoint immunotherapies, surgical resection,<br />
and radiotherapy has demonstrated promising results for the treatment of<br />
cancer patients.<br />
Access Report Summary with Detailed TOC on “<strong>OX</strong>-<strong>40</strong> <strong>Receptor</strong> Agonist<br />
Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent,<br />
Designation, Collaboration, and Other Developments” at:<br />
https://www.psmarketresearch.com/market-analysis/ox<strong>40</strong>-receptor-agonisttherapeutics-pipeline
<strong>OX</strong>-<strong>40</strong> <strong>Receptor</strong> Agonist Therapeutics<br />
Insights on procedure segments<br />
According to the research findings, most of the drug candidates of <strong>OX</strong>-<strong>40</strong><br />
receptor agonist therapeutics pipeline are being developed as a monoclonal<br />
antibody.<br />
Maximum drugs being developed as monoclonal<br />
antibody<br />
Most of the companies are focused on developing their drug candidates as<br />
monoclonal antibodies in the <strong>OX</strong>-<strong>40</strong> receptor agonist therapeutics pipeline.<br />
Monoclonal antibodies are homogenous and consistent. Also, they can be<br />
renewably generated once a suitable hybridoma is developed and are highly<br />
sensitive to small changes in both salt concentration and ph.
<strong>OX</strong>-<strong>40</strong> <strong>Receptor</strong> Agonist Therapeutics<br />
Various collaborations for <strong>OX</strong>-<strong>40</strong> receptor agonist<br />
drug development<br />
In November 2015, GlaxoSmithKline plc and Merck & Co., Inc. entered into<br />
a collaboration to initiate the Phase I clinical trial designed to evaluate<br />
GSK3174998 as monotherapy in combination with Merck’s anti-PD-1<br />
therapy, Keytruda (pembrolizumab). Some of the key players developing<br />
drugs as <strong>OX</strong>-<strong>40</strong> receptor agonist for the treatment of various indications<br />
include MedImmune, LLC, Agenus Inc., Pfizer Inc., GlaxoSmithKline plc and<br />
others.
<strong>OX</strong>-<strong>40</strong> <strong>Receptor</strong> Agonist Therapeutics<br />
Download report sample at:<br />
https://www.psmarketresearch.com/market-analysis/ox<strong>40</strong>-<br />
receptor-agonist-therapeutics-pipeline/report-sample
GET IN TOUCH<br />
THANK YOU!<br />
For information regarding permissions and other queries<br />
Kindly write to:<br />
enquiry@psmarketresearch.com<br />
US/Canada Toll-Free: 1-888-778-7886<br />
www.psmarketresearch.com
Change language